| 1 |
Chambers DC， Cherikh WS， Harhay MO， et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation：thirty-sixth adult lung and heartlung transplantation report-2019； Focus theme：donor and recipient size match［J］. J Heart Lung Transplant， 2019， 38（10）：1042-1055.
|
| 2 |
Singh TP， Cherikh WS， Hsich E， et al. Graft survival in primary thoracic organ transplant recipients：a special report from the International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation［J］. J Heart Lung Transplant， 2023， 42（10）：1321-1333.
|
| 3 |
Hart A， Pfeiffer RM， Morawski BM， et al. Mortality among solid organ transplant recipients with a pretransplant cancer diagnosis［J］.Am J Transplant， 2023， 23（2）：257-264.
|
| 4 |
Van Raemdonck D， Vos R， Yserbyt J， et al. Lung cancer：a rare indication for， but frequent complication after lung transplantation［J］. J Thorac Dis， 2016， 8（Suppl 11）：S915-S924.
|
| 5 |
Vicary GW， Roman J. Targeting the mammalian target of rapamycin in lung cancer［J］. Am J Med Sci， 2016， 352（5）：507-516.
|
| 6 |
Abdel-Wahab N， Safa H， Abudayyeh A， et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients：an institutional experience and a systematic review of the literature［J］. J Immunother Cancer， 2019， 7（1）：106.
|
| 7 |
Tian T， Li X， Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy［J］. Int J Mol Sci， 2019， 20（3）：755.
|
| 8 |
Assi HI， Kamphorst AO， Moukalled NM， et al. Immune checkpoint inhibitors in advanced non-small cell lung cancer［J］. Cancer，2018， 124（2）：248-261.
|
| 9 |
Kittai AS， Oldham H， Cetnar J， et al. Immune checkpoint inhibitors in organ transplant patients［J］. J Immunother， 2017， 40（7）：277-281.
|
| 10 |
Cai J， Jiang H， Li S， et al. The landscape of actionable genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in Chinese patients with non-small cell lung cancer［J］. Front Oncol， 2022， 11：751106.
|
| 11 |
Litvak AM， Paik PK， Woo KM， et al. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers［J］. J Thorac Oncol， 2014， 9（11）：1669-1674.
|
| 12 |
Dankner M， Rose AA， Rajkumar S， et al. Classifying BRAF alterations in cancer：new rational therapeutic strategies for actionable mutations［J］. Oncogene， 2018， 37（24）：3183-3199.
|
| 13 |
Cardarella S， Ogino A， Nishino M， et al. Clinical， pathologic， and biologic features associated with BRAF mutations in non-small cell lung cancer［J］. Clin Cancer Res， 2013， 19（16）：4532-4540.
|
| 14 |
Couraud S， Barlesi F， Fontaine-Deraluelle C， et al. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations：results from the French Cooperative Thoracic Intergroup biomarkers France study［J］. Eur J Cancer， 2019， 116：86-97.
|
| 15 |
Guisier F， Dubos-Arvis C， Viñas F， et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF， HER2， or MET mutations or RET translocation：GFPC 01-2018［J］. J Thorac Oncol， 2020， 15（4）：628-636.
|
| 16 |
Planchard D， Kim TM， Mazieres J， et al. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer：a singlearm， multicentre， open-label， phase 2 trial［J］. Lancet Oncol，2016， 17（5）：642-650.
|
| 17 |
Subbiah V， Gervais R， Riely G， et al. Efficacy of vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation：an open-label， single-arm cohort of the histology-independent VEBASKET study［J］. JCO Precis Oncol， 2019， 3：PO.18.00266.
|
| 18 |
Planchard D， Smit EF， Groen HJ， et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer：an open-label， phase 2 trial［J］. Lancet Oncol， 2017， 18（10）：1307-1316.
|
| 19 |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南2023［D］. 北京：人民卫生出版社， 2024.
|
| 20 |
Riely GJ， Marks J， Pao W. KRAS mutations in non-small cell lung cancer［J］. Proc Am Thorac Soc， 2009， 6（2）：201-205.
|
| 21 |
Cai D， Hu C， Li L， et al. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients［J］. Cancer Med， 2020， 9（1）：84-93.
|
| 22 |
Hong DS， Fakih MG， Strickler JH， et al. KRASG12C inhibition with sotorasib in advanced solid tumors［J］. N Engl J Med， 2020，383（13）：1207-1217.
|
| 23 |
Dy GK， Govindan R， Velcheti V， et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer：2-year analysis of CodeBreaK 100［J］. J Clin Oncol， 2023， 41（18）：3311-3317.
|
| 24 |
Jänne PA， Riely GJ， Gadgeel SM， et al. Adagrasib in non-smallcell lung cancer harboring a KRASG12C mutation［J］. N Engl J Med， 2022， 387（2）：120-131.
|
| 25 |
Reck M， Carbone DP， Garassino M， et al. Targeting KRAS in nonsmall-cell lung cancer：recent progress and new approaches［J］. Ann Oncol， 2021，32（9）：1101-1110.
|
| 26 |
Tan AC， Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations［J］. J Clin Oncol， 2022，40（6）：611-625.
|